SCHEMBL6414136

SCHEMBL6414136

CC(=O)N(CCc1ccc(F)cc1)Cc1ccccc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.47
ALDH1A1 P00352 2/20 0.47
EGFR P00533 3/20 0.46
ERBB2 P04626 3/20 0.46
GAA P10253 2/20 0.46
LMNA P02545 2/20 0.46
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
LPAR1 Q92633 1/20 0.41
LPAR5 Q9H1C0 1/20 0.41
TAAR1 Q96RJ0 1/20 0.41
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 1/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6419946 0.88 EGFR (0.55) KDM4EALDH1A1EGFRERBB2LMNA
SCHEMBL6414593 0.85 EGFR (0.47) KDM4EALDH1A1EGFRERBB2GAA
SCHEMBL10399412 0.82 LMNA (0.56) KDM4EALDH1A1GAALMNAMEN1
SCHEMBL6417312 0.81 KDM4E (0.47) KDM4EALDH1A1EGFRERBB2GAA
SCHEMBL6417318 0.81 KDM4E (0.47) KDM4EALDH1A1EGFRERBB2GAA
SCHEMBL6410998 0.79 EGFR (0.43) KDM4EALDH1A1EGFRERBB2GAA
SCHEMBL6411002 0.79 EGFR (0.43) KDM4EALDH1A1EGFRERBB2GAA
SCHEMBL6411621 0.75 LMNA (0.50) KDM4EALDH1A1GAALMNAMEN1
SCHEMBL5577865 0.74 GAA (0.62) KDM4EGAALMNAMEN1KMT2A
SCHEMBL6415124 0.74 SLC2A4 (0.47) KDM4EALDH1A1GAALMNATAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050043370-A1 HIV integrase inhibitors WALKER MICHAEL A (US) 2005-02-24 US disclosed
US-6803378-B2 FOR THERAPY AND PROPHYLAXIS OF ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS), OR ARC BRISTOL-MYERS SQUIBB COMPANY 2004-10-12 US disclosed
US-20030181490-A1 HIV integrase inhibitors WALKER MICHAEL A (US) 2003-09-25 US disclosed
EP-1322599-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-07-02 EP disclosed
US-20030027847-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2003-02-06 US disclosed
WO-2001096283-A9 HIV INTEGRASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2002-10-17 WO disclosed
WO-2001096283-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043370-A1 HIV integrase inhibitors AKR1C3, CBR3, CBR1 KDM4E 1795/4885ALDH1A1 1020/4885EGFR 782/4885
US-20030181490-A1 HIV integrase inhibitors CBR1, CCR5, CCR1 KDM4E 847/4885ALDH1A1 239/4885EGFR 1414/4885
US-20030027847-A1 HIV integrase inhibitors CBR1, CCR5, CCR1 KDM4E 847/4885ALDH1A1 239/4885EGFR 1414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.